Kamada (KMDA) Posts Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Share on StockTwits

Kamada (NASDAQ:KMDA) announced its earnings results on Tuesday. The biotechnology company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.08, Morningstar.com reports. Kamada had a net margin of 19.48% and a return on equity of 22.74%. The business had revenue of $26.80 million during the quarter, compared to the consensus estimate of $22.87 million. Kamada updated its FY 2019 guidance to EPS.

Shares of KMDA traded up $0.02 during mid-day trading on Wednesday, reaching $5.77. 17,476 shares of the company’s stock were exchanged, compared to its average volume of 152,947. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.70 and a quick ratio of 3.46. Kamada has a 52-week low of $4.55 and a 52-week high of $6.70. The stock has a market cap of $227.08 million, a price-to-earnings ratio of 10.49 and a beta of 1.15.

Several equities research analysts have recently weighed in on KMDA shares. Zacks Investment Research upgraded shares of Kamada from a “hold” rating to a “buy” rating and set a $6.25 target price for the company in a research note on Thursday, February 14th. HC Wainwright reiterated a “buy” rating and set a $11.00 target price on shares of Kamada in a research note on Thursday, February 14th.

Institutional investors and hedge funds have recently modified their holdings of the company. Nkcfo LLC acquired a new position in shares of Kamada during the 1st quarter valued at $26,000. Meitav Dash Investments Ltd. lifted its holdings in Kamada by 3.1% in the 1st quarter. Meitav Dash Investments Ltd. now owns 909,912 shares of the biotechnology company’s stock worth $5,201,000 after buying an additional 27,405 shares in the last quarter. Ramsey Quantitative Systems lifted its holdings in Kamada by 341.7% in the 4th quarter. Ramsey Quantitative Systems now owns 36,154 shares of the biotechnology company’s stock worth $181,000 after buying an additional 27,969 shares in the last quarter. Ibex Investors LLC lifted its holdings in Kamada by 14.5% in the 4th quarter. Ibex Investors LLC now owns 308,000 shares of the biotechnology company’s stock worth $1,540,000 after buying an additional 39,000 shares in the last quarter. Finally, Norges Bank acquired a new position in Kamada in the 4th quarter worth $219,000. 12.60% of the stock is owned by institutional investors and hedge funds.

WARNING: This piece was posted by Week Herald and is the property of of Week Herald. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://weekherald.com/2019/05/15/kamada-kmda-posts-quarterly-earnings-results-beats-expectations-by-0-08-eps.html.

Kamada Company Profile

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency.

See Also: Are analyst ratings accurate?

Earnings History for Kamada (NASDAQ:KMDA)

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.